Market Cap : 842 M | Enterprise Value : 820.2 M | PE Ratio : 23.05 | PB Ratio : 10.33 |
---|
NAS:NRC has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NAS:NRC has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Debt-to-EBITDA measures a company's ability to pay off its debt.
National Research's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2022 was $4.3 Mil. National Research's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2022 was $21.2 Mil. National Research's annualized EBITDA for the quarter that ended in Mar. 2022 was $52.3 Mil. National Research's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2022 was 0.49.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's
The historical rank and industry rank for National Research's Debt-to-EBITDA or its related term are showing as below:
During the past 13 years, the highest Debt-to-EBITDA Ratio of National Research was 0.91. The lowest was 0.03. And the median was 0.42.
The historical data trend for National Research's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, National Research's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Healthcare Providers & Services industry and Healthcare sector, National Research's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where National Research's Debt-to-EBITDA falls into.
Debt-to-EBITDA measures a company's ability to pay off its debt.
National Research's Debt-to-EBITDA for the fiscal year that ended in Dec. 2021 is calculated as
Debt-to-EBITDA | = | Total Debt | / | EBITDA | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | EBITDA | |
= | (4.278 | + | 22.269) | / | 56.662 | |
= | 0.47 |
National Research's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2022 is calculated as
Debt-to-EBITDA | = | Total Debt | / | EBITDA | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | EBITDA | |
= | (4.333 | + | 21.161) | / | 52.264 | |
= | 0.49 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2022) EBITDA data.
In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's
Thank you for viewing the detailed overview of National Research's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Jackson Steven D. | officer: President | C/O NATIONAL RESEARCH CORPORATION 1245 Q STREET LINCOLN NE 68508 |
Martin Joann M | director | 6221 ANDREW COURT LINCOLN NE 68512 |
Nunnelly John N | director | P.O. BOX 2175 AMHERST MA 01004 |
Karas Kevin R | officer: SVP Finance, CFO, Treas & Secy | C/O NATIONAL RESEARCH CORPORATION 1245 Q STREET LINCOLN NE 68508 |
Berwick Donald M | director | C/O NATIONAL RESEARCH CORPORATION 1245 Q STREET LINCOLN NE 68508 |
Mowry Barbara | director | P.O. BOX 103115 DENVER CO 80250 |
Amandla Mk Trust | 10 percent owner | C/O THE BRYN MAWR TRUST COMPANY OF DELAW 20 MONTCHANIN RD, SUITE 100 GREENVILLE DE 19807 |
Hays Michael D. | director, officer: CEO | C/O NATIONAL RESEARCH CORPORATION 1245 Q STREET LINCOLN NE 68508 |
K/i/e Trust Under Agreement 10/24/18 | 10 percent owner | C/O BESSEMER TRUST COMPANY OF DELAWARE 1007 N. ORANGE ST., SUITE 1450 WILMINGTON DE 19801 |
Endacott Kent E. | 10 percent owner | C/O WOODS & AITKEN LLP 301 SOUTH 13TH STREET, SUITE 500 LINCOLN NE 68508 |
Beans Patrick E | director, officer: CFO and Secretary | AMANDLA LLC 709 PIER 2 LINCOLN NE 68528 |
Warden Gail L | director | 250 WASHINGTON RD GROSSE POINTE MI 48230 |
Henricks Susan L | officer: President and COO | C/O NATIONAL RESEARCH CORPORATION 1245 Q STREET LINCOLN NE 68508 |
Schorr Paul C Iii | director | PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"> Ownership Information: SCHORR PAUL C III a.header:link {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:visited {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:hover {color: #191970;} |
Peetz Jeffery T | 10 percent owner | WOODS & AITKEN LLP 301 SOUTH 13TH STREET, SUITE 500 LINCOLN NE 68508 |
From GuruFocus
By GlobeNewswire 02-14-2022
By Omar Venerio 11-04-2020
Other Sources
By Seekingalpha 2022-02-09